Journal of pediatric and adolescent gynecology · 2009
Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.
Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Narsing Rao Laddiperla, Jacob Jubbin Jagan, Paul Thomas V, Rajarathinam Simon, Thomas Nihal, Seshadri Mandalam S
Аннотация
STUDY OBJECTIVE: To study the clinical, metabolic and adverse effects of pioglitazone over a period of 6 months in obese adolescent and young adults with polycystic ovary syndrome.
DESIGN: This was an open labeled study. Each patient served as her own control.
SETTING: Outpatient department of a university affiliated teaching hospital.
PARTICIPANTS: Unmarried women (age 15-25 yrs) with chronic anovulatory cycles and obesity, and with clinical evidence of hyperandrogenism.
INTERVENTIONS: Pioglitazone at a dose of 30 mg once daily for a period of 6 months along with dietary advice and exercise.
MAIN OUTCOME MEASURES: Resumption of normal menstrual cycles, clinical improvement in hyperandrogenism and changes in insulin resistance measured by fasting glucose insulin ratios.
RESULTS: Twenty-two women were enrolled. At the end of the study period 91% of the subjects had regularization of menstrual cycles. There was no change in the modified Ferriman-Gallwey hirsutism scores. Decline in fasting insulin levels at the end of the study was 45.6% from baseline along with significant increase in the fasting glucose/insulin ratio from baseline.
CONCLUSION: Administration of pioglitazone for 6 months along with advice about diet and physical activity in obese adolescents and young adult women with polycystic ovary syndrome results in significant improvements in menstrual frequency. There is a significant improvement in insulin resistance using the G/I ratio (<7.5 mg/10(-4) U) as the biochemical marker.
DESIGN: This was an open labeled study. Each patient served as her own control.
SETTING: Outpatient department of a university affiliated teaching hospital.
PARTICIPANTS: Unmarried women (age 15-25 yrs) with chronic anovulatory cycles and obesity, and with clinical evidence of hyperandrogenism.
INTERVENTIONS: Pioglitazone at a dose of 30 mg once daily for a period of 6 months along with dietary advice and exercise.
MAIN OUTCOME MEASURES: Resumption of normal menstrual cycles, clinical improvement in hyperandrogenism and changes in insulin resistance measured by fasting glucose insulin ratios.
RESULTS: Twenty-two women were enrolled. At the end of the study period 91% of the subjects had regularization of menstrual cycles. There was no change in the modified Ferriman-Gallwey hirsutism scores. Decline in fasting insulin levels at the end of the study was 45.6% from baseline along with significant increase in the fasting glucose/insulin ratio from baseline.
CONCLUSION: Administration of pioglitazone for 6 months along with advice about diet and physical activity in obese adolescents and young adult women with polycystic ovary syndrome results in significant improvements in menstrual frequency. There is a significant improvement in insulin resistance using the G/I ratio (<7.5 mg/10(-4) U) as the biochemical marker.